Mounjaro side effects and stopping GLP-1s: what's real?

What did @becomingher78 actually say?

Here's the awkward part: the transcript provided doesn't actually contain the claims listed in the video caption. What we have on record is a spoken-word or song-style monologue about self-love and personal transformation, not a breakdown of Mounjaro side effects. The caption, however, is specific: anxiety starting around week eight, constipation and stomach pain described as "unbearable," and a note that the drug helped blood sugar but not enough with weight loss to justify staying on it. This fact-check will assess those captioned claims against the available evidence, because that's what viewers actually read and acted on.

To be clear about what @becomingher78 described: stopping tirzepatide (Mounjaro) after roughly eleven weeks due to anxiety, gastrointestinal distress, and limited perceived weight benefit. That's a real experience shared by a meaningful number of people on GLP-1 and GIP/GLP-1 dual agonist therapies. Whether the science supports those specific complaints is worth examining carefully.

Does the science back this up?

On the GI side, yes, pretty unambiguously. On anxiety, the picture is messier and less settled than the caption implies.

Gastrointestinal side effects from tirzepatide are among the most consistently documented findings in the clinical literature. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that nausea, diarrhea, vomiting, and constipation were the most common adverse events, reported by 17 to 44 percent of participants depending on dose. Constipation specifically showed up in roughly 17 percent of patients on the 15 mg dose. "Unbearable" is subjective, but the underlying biology is real: tirzepatide slows gastric emptying significantly, and for some people, that creates persistent, difficult-to-manage GI symptoms that don't fully resolve.

Anxiety is a different story. It doesn't appear as a primary adverse event in the major tirzepatide trials. However, GLP-1 receptors are present in regions of the brain associated with mood regulation, and some case reports and user-reported data from pharmacovigilance databases have flagged mood changes in people on GLP-1 class drugs. A 2023 FDA review did not establish a causal link between semaglutide or tirzepatide and anxiety or depression, though monitoring continues.

What did they get wrong (or right)?

The constipation and stomach pain complaints are well-supported. That's a give. The GI burden of tirzepatide is real, dose-dependent, and a documented driver of discontinuation. Giving credit where it's due: this is one of the more honest accounts of why people actually stop these medications.

The anxiety claim is where things get shaky. Attributing anxiety specifically to Mounjaro after eight weeks is not something the current evidence can confirm or deny for any individual. Anxiety can emerge from rapid weight changes, altered eating patterns, caloric restriction effects on neurotransmitter availability, or entirely unrelated life circumstances. Presenting it as a medication-caused side effect, without that nuance, is misleading even if it felt entirely real to the creator. Personal experience is valid data about a person's life. It's not clinical evidence of causation.

The observation that tirzepatide helped blood sugar but felt underwhelming for weight is also worth flagging: eleven weeks is early. The SURMOUNT-1 data shows meaningful weight loss often accelerating after week twelve as titration continues. Stopping before reaching therapeutic dose makes it genuinely difficult to assess efficacy.

What should you actually know?

If you're on tirzepatide and experiencing GI side effects, you're not imagining it and you're not alone. But there are meaningful differences between pushing through a temporary adjustment period and experiencing something that warrants a real medication change.

A few things the research actually tells us:

• GI side effects from tirzepatide are most intense during dose escalation and typically decrease over time, though they don't disappear for everyone (Jastreboff et al., 2022, NEJM).
• Discontinuation due to adverse events in SURMOUNT-1 occurred in about 4.3 percent of participants on the highest dose, suggesting most people do tolerate the drug long-term, but a meaningful minority don't.
• There is no confirmed causal relationship between tirzepatide and anxiety in regulatory-level evidence as of 2024. That doesn't mean your experience isn't real. It means the mechanism hasn't been established.
• Stopping a GLP-1 or dual agonist without medical guidance carries its own risks, particularly for people managing type 2 diabetes, where glycemic control can deteriorate quickly after discontinuation.

The creator's decision to stop is personal and valid. But presenting the anxiety claim as a documented drug effect to 118,000 viewers, without qualification, has consequences for how those viewers understand their own treatment options. That part deserves a correction.